Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Jun 07, 2022 6:19pm
205 Views
Post# 34738581

RE:1st publication of Phase I trial now available online

RE:1st publication of Phase I trial now available online11, 9, 24, 24, 12, 18 are the numbers of unsuccessful BCG doses our patients 1-6 received before enrolling in our Ph. 1b.

So our 2-doses treatment is kind of revolutionnary, especially when considering that patient #5 (12 unsuccessful BCG doses) and patient #6 (18 unsuccessful BCG doses) were cancer-free after 1 dose (ph. 1b was only 1 dose).

BCG unefficacy (24 doses!!!) was probably responsable for the worsening condition ... and death of patient #4 when you think of all the time it gave to the tumor to go deeper and become metastasic.  This patient paid the price and it's time for TLD-1433 to replace BCG.
<< Previous
Bullboard Posts
Next >>